Healthcare provider profile · identity verified

Myrtle E Goore, MD

Family Practice · MONTGOMERY, AL · NPI 1942366745

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	342	104
Rosuvastatin Calcium	Rosuvastatin Calcium	239	76
Levothyroxine Sodium	Levothyroxine Sodium	188	41
Atorvastatin Calcium	Atorvastatin Calcium	169	51
Omeprazole	Omeprazole	135	47
Hydrochlorothiazide	Hydrochlorothiazide	130	41
Alprazolam	Alprazolam	127	21
Montelukast Sodium	Montelukast Sodium	120	38
Telmisartan	Telmisartan	119	33
Losartan Potassium	Losartan Potassium	115	32
Zolpidem Tartrate	Zolpidem Tartrate	115	13
Carvedilol	Carvedilol	108	27
Pravastatin Sodium	Pravastatin Sodium	102	28
Alendronate Sodium	Alendronate Sodium	96	26
Furosemide	Furosemide	84	21
Tramadol Hcl	Tramadol Hcl	84	16
Metformin Hcl	Metformin Hcl	81	19
Pantoprazole Sodium	Pantoprazole Sodium	80	24
Trazodone Hcl	Trazodone Hcl	80	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	74	suppressed
Meloxicam	Meloxicam	71	24
Gabapentin	Gabapentin	70	16
Ibuprofen	Ibuprofen	70	19
Fluconazole	Fluconazole	69	31
Metoprolol Tartrate	Metoprolol Tartrate	69	16
Raloxifene Hcl	Raloxifene Hcl	64	21
Eliquis	Apixaban	58	12
Albuterol Sulfate Hfa	Albuterol Sulfate	57	20
Lisinopril	Lisinopril	56	17
Linzess	Linaclotide	54	14
Baclofen	Baclofen	52	suppressed
Ozempic	Semaglutide	52	11
Estradiol	Estradiol	51	12
Ezetimibe	Ezetimibe	51	18
Metformin Hcl Er	Metformin Hcl	50	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	50	17
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	48	23
Methylprednisolone	Methylprednisolone	47	34
Potassium Chloride	Potassium Chloride	47	13
Hydralazine Hcl	Hydralazine Hcl	46	11
Olmesartan Medoxomil	Olmesartan Medoxomil	40	13
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	40	suppressed
Amoxicillin	Amoxicillin	38	24
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	37	suppressed
Clopidogrel	Clopidogrel Bisulfate	37	11
Diclofenac Sodium	Diclofenac Sodium	36	suppressed
Metoprolol Succinate	Metoprolol Succinate	35	11
Simvastatin	Simvastatin	34	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	suppressed
Famotidine	Famotidine	32	11
Glyxambi	Empagliflozin/Linagliptin	32	suppressed
Ondansetron Hcl	Ondansetron Hcl	32	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Methocarbamol	Methocarbamol	31	12
Mounjaro	Tirzepatide	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	13
Irbesartan	Irbesartan	30	suppressed
Allopurinol	Allopurinol	29	suppressed
Sucralfate	Sucralfate	29	suppressed
Verapamil Er	Verapamil Hcl	29	suppressed
Estradiol (Twice Weekly)	Estradiol	27	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	26	suppressed
Sertraline Hcl	Sertraline Hcl	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	suppressed
Breo Ellipta	Fluticasone/Vilanterol	24	suppressed
Clonazepam	Clonazepam	24	suppressed
Glimepiride	Glimepiride	24	suppressed
Valacyclovir	Valacyclovir Hcl	24	suppressed
Atenolol	Atenolol	23	suppressed
Clonidine Hcl	Clonidine Hcl	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Azithromycin	Azithromycin	22	20
Escitalopram Oxalate	Escitalopram Oxalate	22	suppressed
Farxiga	Dapagliflozin Propanediol	22	suppressed
Synthroid	Levothyroxine Sodium	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	21	suppressed
Januvia	Sitagliptin Phosphate	21	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	21	suppressed
Lorazepam	Lorazepam	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Spironolactone	Spironolactone	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	15
Jardiance	Empagliflozin	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Prednisone	Prednisone	16	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Nystatin	Nystatin	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	13
Azelastine Hcl	Azelastine Hcl	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	12	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Felodipine Er	Felodipine	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Nebivolol Hcl	Nebivolol Hcl	11	suppressed
Terbinafine Hcl	Terbinafine Hcl	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error